Milind Rao1, Wenxuan Yang, Alexander M Seifalian, Marc C Winslet. 1. University Department of Surgery, Royal Free and University College Medical School, Royal Free Hospital, University College London, Pond Street, NW3 2QG, London, UK.
Abstract
BACKGROUND: Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins. It exists in two isoforms: COX-1 which is constitutively expressed and COX-2 which is an inducible form activated by a variety of cytokines during inflammation. DISCUSSION: Interest in this enzyme arose in the early 1990s when, following epidemiological studies, aspirin (which is a COX inhibitor) was found to reduce the risk of colorectal cancer. Since then various studies to decipher the mechanisms by which COX reduces the development of colorectal cancer have been undertaken. One of the mechanisms being studied is its role in the angiogenesis of colorectal cancer. Angiogenesis of its own has been well established as a key factor in the development of tumours. Agents that specifically inhibit COX-2 are now in clinical development and have been licensed to be used in patients with familial adenomatosis polyposis. CONCLUSION: What needs to be determined is whether the antiangiogenic effects of COX-2 inhibitors can be used in the prevention and/or treatment of colorectal cancer and its metastases.
BACKGROUND: Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins. It exists in two isoforms: COX-1 which is constitutively expressed and COX-2 which is an inducible form activated by a variety of cytokines during inflammation. DISCUSSION: Interest in this enzyme arose in the early 1990s when, following epidemiological studies, aspirin (which is a COX inhibitor) was found to reduce the risk of colorectal cancer. Since then various studies to decipher the mechanisms by which COX reduces the development of colorectal cancer have been undertaken. One of the mechanisms being studied is its role in the angiogenesis of colorectal cancer. Angiogenesis of its own has been well established as a key factor in the development of tumours. Agents that specifically inhibit COX-2 are now in clinical development and have been licensed to be used in patients with familial adenomatosis polyposis. CONCLUSION: What needs to be determined is whether the antiangiogenic effects of COX-2 inhibitors can be used in the prevention and/or treatment of colorectal cancer and its metastases.
Authors: H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla Journal: Cancer Res Date: 1995-09-01 Impact factor: 12.701
Authors: B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald Journal: Proc Natl Acad Sci U S A Date: 1999-01-05 Impact factor: 11.205
Authors: M Fukutake; S Nakatsugi; T Isoi; M Takahashi; T Ohta; S Mamiya; Y Taniguchi; H Sato; K Fukuda; T Sugimura; K Wakabayashi Journal: Carcinogenesis Date: 1998-11 Impact factor: 4.944
Authors: Syed Waqas Ali Shah; Muhammad Ishfaq; Muhammad Nasrullah; Abdul Qayum; Muhammad Usman Akhtar; Hyeonsoo Jo; Muhammad Hussain; Xiaohua Teng Journal: Environ Sci Pollut Res Int Date: 2020-01-22 Impact factor: 4.223
Authors: Patricia Sebastian-Leon; Enrique Vidal; Pablo Minguez; Ana Conesa; Sonia Tarazona; Alicia Amadoz; Carmen Armero; Francisco Salavert; Antonio Vidal-Puig; David Montaner; Joaquín Dopazo Journal: BMC Syst Biol Date: 2014-10-25